PDB Short entry for 2OFV HEADER TRANSFERASE 04-JAN-07 2OFV TITLE CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LCK KINASE DOMAIN, RESIDUES 231-497; COMPND 5 SYNONYM: P56-LCK, LYMPHOCYTE CELL-SPECIFIC PROTEIN-TYROSINE KINASE, COMPND 6 LSK, T CELL- SPECIFIC PROTEIN-TYROSINE KINASE; COMPND 7 EC: 2.7.10.2; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LCK; SOURCE 6 EXPRESSION_SYSTEM: INSECT CELL; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS LCK, KINASE DOMAIN, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR X.HUANG REVDAT 3 30-AUG-23 2OFV 1 REMARK SEQADV REVDAT 2 24-FEB-09 2OFV 1 VERSN REVDAT 1 27-FEB-07 2OFV 0 JRNL AUTH E.F.DIMAURO,J.NEWCOMB,J.J.NUNES,J.E.BEMIS,C.BOUCHER, JRNL AUTH 2 J.L.BUCHANAN,W.H.BUCKNER,V.J.CEE,L.CHAI,H.L.DEAK, JRNL AUTH 3 L.F.EPSTEIN,T.FAUST,P.GALLANT,S.D.GEUNS-MEYER,A.GORE,Y.GU, JRNL AUTH 4 B.HENKLE,B.L.HODOUS,F.HSIEH,X.HUANG,J.L.KIM,J.H.LEE, JRNL AUTH 5 M.W.MARTIN,C.E.MASSE,D.C.MCGOWAN,D.METZ,D.MOHN, JRNL AUTH 6 K.A.MORGENSTERN,A.OLIVEIRA-DOS-SANTOS,V.F.PATEL,D.POWERS, JRNL AUTH 7 P.E.ROSE,S.SCHNEIDER,S.A.TOMLINSON,Y.-Y.TUDOR,S.M.TURCI, JRNL AUTH 8 A.A.WELCHER,R.D.WHITE,H.ZHAO,L.ZHU,X.ZHU JRNL TITL DISCOVERY OF AMINOQUINAZOLINES AS POTENT, ORALLY JRNL TITL 2 BIOAVAILABLE INHIBITORS OF LCK: SYNTHESIS, SAR, AND IN VIVO JRNL TITL 3 ANTI-INFLAMMATORY ACTIVITY JRNL REF J.MED.CHEM. V. 49 5671 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16970394 JRNL DOI 10.1021/JM0605482 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 41284 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.274 REMARK 3 FREE R VALUE : 0.301 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3878 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 62 REMARK 3 SOLVENT ATOMS : 271 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.460 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OFV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 11-JAN-07. REMARK 100 THE DEPOSITION ID IS D_1000041083. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41290 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.1 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.09100 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 16.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 55.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.28100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1QPC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.56 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.71 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.3 M MGACETATE, 5-12.5% PEG8000, PH REMARK 280 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 71.33000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.44500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 71.33000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 33.44500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICAL ASSEMBLY IS A MONOMER. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 THR A 226 REMARK 465 GLN A 227 REMARK 465 LYS A 228 REMARK 465 PRO A 229 REMARK 465 GLN A 230 REMARK 465 SER A 279 REMARK 465 MET A 280 REMARK 465 SER A 281 REMARK 465 PRO A 282 REMARK 465 ASP A 283 REMARK 465 ALA A 284 REMARK 465 PHE A 285 REMARK 465 ARG A 387 REMARK 465 LEU A 388 REMARK 465 ILE A 389 REMARK 465 GLU A 390 REMARK 465 ASP A 391 REMARK 465 ASN A 392 REMARK 465 GLU A 393 REMARK 465 TYR A 394 REMARK 465 THR A 395 REMARK 465 ALA A 396 REMARK 465 ARG A 397 REMARK 465 GLU A 398 REMARK 465 GLY A 399 REMARK 465 ALA A 400 REMARK 465 LYS A 401 REMARK 465 PHE A 402 REMARK 465 PRO A 403 REMARK 465 THR A 499 REMARK 465 ALA A 500 REMARK 465 THR A 501 REMARK 465 GLU A 502 REMARK 465 THR B 226 REMARK 465 GLN B 227 REMARK 465 LYS B 228 REMARK 465 PRO B 229 REMARK 465 GLN B 230 REMARK 465 LYS B 231 REMARK 465 SER B 279 REMARK 465 MET B 280 REMARK 465 SER B 281 REMARK 465 PRO B 282 REMARK 465 ASP B 283 REMARK 465 ASN B 392 REMARK 465 GLU B 393 REMARK 465 TYR B 394 REMARK 465 THR B 395 REMARK 465 ALA B 396 REMARK 465 ARG B 397 REMARK 465 GLU B 398 REMARK 465 GLY B 399 REMARK 465 ALA B 400 REMARK 465 LYS B 401 REMARK 465 PHE B 402 REMARK 465 GLY B 443 REMARK 465 MET B 444 REMARK 465 THR B 445 REMARK 465 ASN B 446 REMARK 465 PRO B 447 REMARK 465 GLU B 448 REMARK 465 VAL B 449 REMARK 465 ARG B 455 REMARK 465 ALA B 500 REMARK 465 THR B 501 REMARK 465 GLU B 502 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 231 CG CD CE NZ REMARK 470 GLN A 277 CG CD OE1 NE2 REMARK 470 LEU A 286 CG CD1 CD2 REMARK 470 THR A 308 OG1 CG2 REMARK 470 GLN A 309 CG CD OE1 NE2 REMARK 470 ASP A 374 CG OD1 OD2 REMARK 470 ILE A 404 CG1 CG2 CD1 REMARK 470 ILE A 450 CG1 CG2 CD1 REMARK 470 GLU A 454 CG CD OE1 OE2 REMARK 470 LYS B 276 CG CD CE NZ REMARK 470 GLN B 277 CG CD OE1 NE2 REMARK 470 PHE B 285 CG CD1 CD2 CE1 CE2 CZ REMARK 470 GLN B 298 CG CD OE1 NE2 REMARK 470 GLN B 309 CG CD OE1 NE2 REMARK 470 LYS B 335 CG CD CE NZ REMARK 470 ASP B 374 CG OD1 OD2 REMARK 470 LEU B 376 CG CD1 CD2 REMARK 470 GLU B 390 CG CD OE1 OE2 REMARK 470 ASP B 391 CG OD1 OD2 REMARK 470 PRO B 403 CG CD REMARK 470 ILE B 404 CG1 CG2 CD1 REMARK 470 LYS B 405 CG CD CE NZ REMARK 470 HIS B 436 CG ND1 CD2 CE1 NE2 REMARK 470 ILE B 450 CG1 CG2 CD1 REMARK 470 ARG B 461 CG CD NE CZ NH1 NH2 REMARK 470 ASP B 463 CG OD1 OD2 REMARK 470 GLU B 468 CG CD OE1 OE2 REMARK 470 LEU B 472 CG CD1 CD2 REMARK 470 LYS B 478 CG CD CE NZ REMARK 470 ARG B 491 CG CD NE CZ NH1 NH2 REMARK 470 THR B 499 OG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LYS B 335 N - CA - C ANGL. DEV. = -17.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 363 -17.57 81.39 REMARK 500 ASP A 364 47.95 -141.72 REMARK 500 PHE A 383 29.24 -146.70 REMARK 500 LEU A 385 16.66 54.91 REMARK 500 ASN A 464 2.99 80.08 REMARK 500 TRP B 238 4.24 -152.54 REMARK 500 THR B 330 150.74 -49.00 REMARK 500 ILE B 334 7.63 55.53 REMARK 500 ILE B 338 -38.22 -32.42 REMARK 500 ARG B 363 -17.06 73.02 REMARK 500 SER B 373 -173.73 -65.59 REMARK 500 ASP B 382 105.80 -160.36 REMARK 500 PHE B 383 28.72 -148.26 REMARK 500 ASN B 464 -1.07 105.35 REMARK 500 TRP B 477 36.17 -91.48 REMARK 500 ASP B 496 38.13 -70.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 242 A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 242 B 503 DBREF 2OFV A 226 502 UNP P06239 LCK_HUMAN 226 502 DBREF 2OFV B 226 502 UNP P06239 LCK_HUMAN 226 502 SEQADV 2OFV THR A 226 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN A 227 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS A 228 UNP P06239 CLONING ARTIFACT SEQADV 2OFV PRO A 229 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN A 230 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS A 231 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR A 499 UNP P06239 CLONING ARTIFACT SEQADV 2OFV ALA A 500 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR A 501 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLU A 502 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 226 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN B 227 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS B 228 UNP P06239 CLONING ARTIFACT SEQADV 2OFV PRO B 229 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN B 230 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS B 231 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 499 UNP P06239 CLONING ARTIFACT SEQADV 2OFV ALA B 500 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 501 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLU B 502 UNP P06239 CLONING ARTIFACT SEQRES 1 A 277 THR GLN LYS PRO GLN LYS PRO TRP TRP GLU ASP GLU TRP SEQRES 2 A 277 GLU VAL PRO ARG GLU THR LEU LYS LEU VAL GLU ARG LEU SEQRES 3 A 277 GLY ALA GLY GLN PHE GLY GLU VAL TRP MET GLY TYR TYR SEQRES 4 A 277 ASN GLY HIS THR LYS VAL ALA VAL LYS SER LEU LYS GLN SEQRES 5 A 277 GLY SER MET SER PRO ASP ALA PHE LEU ALA GLU ALA ASN SEQRES 6 A 277 LEU MET LYS GLN LEU GLN HIS GLN ARG LEU VAL ARG LEU SEQRES 7 A 277 TYR ALA VAL VAL THR GLN GLU PRO ILE TYR ILE ILE THR SEQRES 8 A 277 GLU TYR MET GLU ASN GLY SER LEU VAL ASP PHE LEU LYS SEQRES 9 A 277 THR PRO SER GLY ILE LYS LEU THR ILE ASN LYS LEU LEU SEQRES 10 A 277 ASP MET ALA ALA GLN ILE ALA GLU GLY MET ALA PHE ILE SEQRES 11 A 277 GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU ARG ALA ALA SEQRES 12 A 277 ASN ILE LEU VAL SER ASP THR LEU SER CYS LYS ILE ALA SEQRES 13 A 277 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 A 277 THR ALA ARG GLU GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 A 277 ALA PRO GLU ALA ILE ASN TYR GLY THR PHE THR ILE LYS SEQRES 16 A 277 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU ILE SEQRES 17 A 277 VAL THR HIS GLY ARG ILE PRO TYR PRO GLY MET THR ASN SEQRES 18 A 277 PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY TYR ARG MET SEQRES 19 A 277 VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU TYR GLN LEU SEQRES 20 A 277 MET ARG LEU CYS TRP LYS GLU ARG PRO GLU ASP ARG PRO SEQRES 21 A 277 THR PHE ASP TYR LEU ARG SER VAL LEU GLU ASP PHE PHE SEQRES 22 A 277 THR ALA THR GLU SEQRES 1 B 277 THR GLN LYS PRO GLN LYS PRO TRP TRP GLU ASP GLU TRP SEQRES 2 B 277 GLU VAL PRO ARG GLU THR LEU LYS LEU VAL GLU ARG LEU SEQRES 3 B 277 GLY ALA GLY GLN PHE GLY GLU VAL TRP MET GLY TYR TYR SEQRES 4 B 277 ASN GLY HIS THR LYS VAL ALA VAL LYS SER LEU LYS GLN SEQRES 5 B 277 GLY SER MET SER PRO ASP ALA PHE LEU ALA GLU ALA ASN SEQRES 6 B 277 LEU MET LYS GLN LEU GLN HIS GLN ARG LEU VAL ARG LEU SEQRES 7 B 277 TYR ALA VAL VAL THR GLN GLU PRO ILE TYR ILE ILE THR SEQRES 8 B 277 GLU TYR MET GLU ASN GLY SER LEU VAL ASP PHE LEU LYS SEQRES 9 B 277 THR PRO SER GLY ILE LYS LEU THR ILE ASN LYS LEU LEU SEQRES 10 B 277 ASP MET ALA ALA GLN ILE ALA GLU GLY MET ALA PHE ILE SEQRES 11 B 277 GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU ARG ALA ALA SEQRES 12 B 277 ASN ILE LEU VAL SER ASP THR LEU SER CYS LYS ILE ALA SEQRES 13 B 277 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 B 277 THR ALA ARG GLU GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 B 277 ALA PRO GLU ALA ILE ASN TYR GLY THR PHE THR ILE LYS SEQRES 16 B 277 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU ILE SEQRES 17 B 277 VAL THR HIS GLY ARG ILE PRO TYR PRO GLY MET THR ASN SEQRES 18 B 277 PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY TYR ARG MET SEQRES 19 B 277 VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU TYR GLN LEU SEQRES 20 B 277 MET ARG LEU CYS TRP LYS GLU ARG PRO GLU ASP ARG PRO SEQRES 21 B 277 THR PHE ASP TYR LEU ARG SER VAL LEU GLU ASP PHE PHE SEQRES 22 B 277 THR ALA THR GLU HET 242 A 503 31 HET 242 B 503 31 HETNAM 242 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3- HETNAM 2 242 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE HETSYN 242 AMINOQUINAZOLINE 1 FORMUL 3 242 2(C23 H17 F3 N4 O) FORMUL 5 HOH *271(H2 O) HELIX 1 1 PRO A 241 GLU A 243 5 3 HELIX 2 2 LEU A 286 LEU A 295 1 10 HELIX 3 3 SER A 323 LYS A 329 1 7 HELIX 4 4 THR A 330 LYS A 335 1 6 HELIX 5 5 THR A 337 ARG A 358 1 22 HELIX 6 6 ARG A 366 ALA A 368 5 3 HELIX 7 7 ALA A 408 GLY A 415 1 8 HELIX 8 8 THR A 418 THR A 435 1 18 HELIX 9 9 THR A 445 GLU A 454 1 10 HELIX 10 10 PRO A 466 TRP A 477 1 12 HELIX 11 11 ARG A 480 ARG A 484 5 5 HELIX 12 12 THR A 486 ASP A 496 1 11 HELIX 13 13 PRO B 241 GLU B 243 5 3 HELIX 14 14 PHE B 285 LEU B 295 1 11 HELIX 15 15 SER B 323 LEU B 328 1 6 HELIX 16 16 THR B 337 ARG B 358 1 22 HELIX 17 17 ARG B 366 ALA B 368 5 3 HELIX 18 18 PRO B 403 THR B 407 5 5 HELIX 19 19 ALA B 408 GLY B 415 1 8 HELIX 20 20 THR B 418 VAL B 434 1 17 HELIX 21 21 PRO B 466 TRP B 477 1 12 HELIX 22 22 ARG B 480 ARG B 484 5 5 HELIX 23 23 THR B 486 ASP B 496 1 11 SHEET 1 A 5 LEU A 245 GLY A 254 0 SHEET 2 A 5 GLY A 257 TYR A 264 -1 O VAL A 259 N LEU A 251 SHEET 3 A 5 THR A 268 LEU A 275 -1 O VAL A 272 N TRP A 260 SHEET 4 A 5 ILE A 312 THR A 316 -1 O ILE A 312 N LEU A 275 SHEET 5 A 5 LEU A 303 VAL A 307 -1 N TYR A 304 O ILE A 315 SHEET 1 B 2 ILE A 370 VAL A 372 0 SHEET 2 B 2 CYS A 378 ILE A 380 -1 O LYS A 379 N LEU A 371 SHEET 1 C 5 LEU B 245 GLY B 254 0 SHEET 2 C 5 GLY B 257 TYR B 264 -1 O VAL B 259 N LEU B 251 SHEET 3 C 5 THR B 268 LEU B 275 -1 O VAL B 272 N TRP B 260 SHEET 4 C 5 ILE B 312 THR B 316 -1 O ILE B 314 N LYS B 273 SHEET 5 C 5 LEU B 303 VAL B 307 -1 N ALA B 305 O ILE B 315 SHEET 1 D 2 ILE B 370 VAL B 372 0 SHEET 2 D 2 CYS B 378 ILE B 380 -1 O LYS B 379 N LEU B 371 CISPEP 1 GLU A 310 PRO A 311 0 -0.92 CISPEP 2 GLU B 310 PRO B 311 0 0.31 SITE 1 AC1 20 VAL A 259 ALA A 271 VAL A 272 LYS A 273 SITE 2 AC1 20 GLU A 288 MET A 292 LEU A 295 LEU A 300 SITE 3 AC1 20 VAL A 301 ILE A 314 THR A 316 GLU A 317 SITE 4 AC1 20 TYR A 318 MET A 319 HIS A 362 ILE A 380 SITE 5 AC1 20 ALA A 381 ASP A 382 PHE A 383 HOH A 630 SITE 1 AC2 21 VAL B 259 ALA B 271 LYS B 273 GLU B 288 SITE 2 AC2 21 MET B 292 LEU B 300 VAL B 301 ILE B 314 SITE 3 AC2 21 THR B 316 GLU B 317 TYR B 318 MET B 319 SITE 4 AC2 21 GLY B 322 TYR B 360 LEU B 371 ILE B 380 SITE 5 AC2 21 ALA B 381 ASP B 382 PHE B 383 ILE B 389 SITE 6 AC2 21 HOH B 518 CRYST1 142.660 66.890 78.510 90.00 112.00 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007010 0.000000 0.002832 0.00000 SCALE2 0.000000 0.014950 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013738 0.00000